S
ACRS icon

SignatureFD’s Aclaris Therapeutics ACRS Stock Holding History

SignatureFD’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-161
Closed -$1.1K – 3126
2023
Q3 		$1.1K Sell
161
-117
-42% -$1K ﹤0.01% 2917
2023
Q2 		$2.88K Sell
278
-20
-7% -$181 ﹤0.01% 2689
2023
Q1 		$2.41K Buy
298
+237
+389% +$3.01K ﹤0.01% 2747
2022
Q4 		$961 Sell
61
-40
-40% -$643 ﹤0.01% 2982
2022
Q3 		$2K Buy
+101
New +$1.59K ﹤0.01% 2723
2022
Q2 		– Sell
-43
Closed -$1K – 3079
2022
Q1 		$1K Sell
43
-20
-32% -$273 ﹤0.01% 2926
2021
Q4 		$1K Buy
+63
New +$954 ﹤0.01% 2855

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

SignatureFD's ACRS Position: Q4 2023 in Review

SignatureFD sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 161 shares — an estimated $1.1K sold.

SignatureFD first reported a position in ACRS in Q4 2021 and held it in 7 quarters. The position peaked at $2.88K in Q2 2023. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

  • SignatureFD reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • SignatureFD sold 161 Aclaris Therapeutics shares in Q4 2023, an estimated $1.1K.
  • SignatureFD first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 7 quarters.
  • SignatureFD's Aclaris Therapeutics position peaked at $2.88K in Q2 2023.
  • 107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.